Plain-English translation of NCT07284927 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing , a new cell-based therapy designed to treat blood cancers (like non-Hodgkin lymphoma and acute lymphoblastic leukemia) that have come back or stopped responding to previous treatments. The main goal right now is to make sure the medication is safe for patients to receive. This is a small study that will enroll about 10 people.
Some patients with blood cancers stop responding to standard treatments, leaving them with few options. This medication represents a new approach using modified cells to fight these cancers, and researchers need to test whether it is safe before moving forward.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive as the study treatment. The trial is small and takes place at a single center, so you would likely have multiple visits for the medication administration and careful monitoring of your safety and response. You would work closely with the research team, who will watch for any side effects and regularly check your blood work and overall health throughout the study.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Enrollment target
~10 participants
Started
December 2025
Primary completion
December 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yang Xu, MD
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.